Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

University of Wisconsin (UW)

Status and phase

Terminated

Phase 2

Conditions

Prostate Cancer

Treatments

Drug: CGC-11047

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00585416

CO06801

47-02-001

HSC2006-0099

Details and patient eligibility

About

The purpose of this research is to determine the effectiveness of CGC-11047 in subjects with metastatic hormone refractory prostate cancer as measured by changes in PSA.

Enrollment

23 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Metastatic hormone refractory prostate cancer.
Eastern Cooperative Oncology Group (ECOG) Performance status of 0-1.
testosterone <50ng/dL. Patients must continue primary androgen deprivation with an LHRH analogue if they have not undergone orchiectomy.
Progressive disease after androgen deprivation.

Exclusion criteria

Patients whose clinical condition would make chemotherapy clearly indicated.
Patients who have received systemic chemotherapy for the treatment of metastatic disease.
Peripheral neuropathy > Grade 1
Prior anti-angiogenic therapy, including thalidomide.
Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure or radiation within 4 weeks prior to study entry.
Patients who have received radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment.
Patients with known brain metastases or history of brain metastases.
History of stroke within 6 months of treatment or other significant neurological limitations.
Patients who have received more than 2 prior investigational treatments.
Uncontrolled intercurrent illness
Patients with a history of a myocardial infarction within the prior 6 months or, hospitalizations for decompensated congestive heart failure within the prior 6 months, or history of significant / symptomatic cardiac arrhythmias